Site‐specific drug delivery

Friend, David R.; Pangburn, Sharon

doi:10.1002/med.2610070104

Cited by 75 publications

(36 citation statements)

References 216 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticles (Carmeliet & Jain 2000) PEG modified gelatin nanoparticles loaded with DNA Intracellular trafficking to tumours and nuclear delivery Liposomes (Fischer et al 1999) FA-PEG-DOPE modified liposomes containing DNA Efficient for pH sensitive endosomal DNA delivery HPMA polymer (Folkman 2002) HPMA-(Gly-Phe-Leu-Gly) linker-TNP 470 complex Selective accumulation in tumour vasculature and prevents TNP-470 from crossing blood-brain barrier Liposomes (Friend & Pangburn 1987) Folate conjugated liposomes Efficient delivery of cytotoxic drug to tumours Nanospheres (Fujita et al 1997) Gelatin nanospheres complexed to DNA Efficient vehicle for gene delivery Nanoparticles (Gale & Yancopoulos 1999) RGD-modified nanoparticles Selective localization of drugs in tumours Nanoparticles (Galle & Krammer 1998) Dextran-drug conjugate incorporated in chitosan nanoparticles Efficient vehicles to suppress tumour volume Nanoparticles (Gaur et al 2000) PLGA nanoparticle conjugated with anti-cancer drug High-loading efficiency and comparable activity to official formulations Microspheres (Gillies & Frechet 2004) Alginate microspheres containing naked DNA (Patri et al 2002a;Gillies & Frechet 2004) (Figure 4). Micelles of PLLA-b-PEO polysulfadimethoxine are pH sensitive due to acidic sulfonamide groups and have been reported to be useful anti-cancer agents .…”

Section: Carrier Systems Formulation Remarksmentioning

confidence: 99%

“…N-(2-Hydroxy propyl) methacrylamide (HPMA) copolymer conjugated to doxorubicin has been shown to reduce cardiotoxicity by 4-5-times due to efficient localization mediated via the EPR effect (Duncan et al 2005). Thus, a drug conjugated to a macromolecule may lead to a far better distribution of the drug (Friend & Pangburn 1987) and EPR provides a passive transport mechanism for the entry of drug into malignant cells (Kaul et al 2003). Macromolecules such as albumins (Lowenthal et al 2005), globulins (Selby 1990) and synthetic polymer accumulate in the tumour tissues because these tissues have a vascular network characterized by both enhanced permeability of the neovasculature and a lack of the lymphatic recovery system (Matsumura & Maeda 1986).…”

Section: Enhanced Permeation and Retention (Epr) Effectmentioning

confidence: 99%

See 1 more Smart Citation

Tumour and dendrimers: a review on drug delivery aspects

Agarwal

Asthana

Gupta

et al. 2008

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Tumour is a morbid state, characterized by spontaneous outgrowth of an abnormal mass of cells. The evolution of tumours is random, disorganized, a condition of numerous mutations. The properties are biased and incompletely comprehended. It is a malignant or benign condition that encompasses its own rules of morphogenesis, an immortal state that elucidates different physiology. It is a pathological crisis that still haunts the minds of scientists, physicians and patients, a complete cure of which is still a dream to be realized. The unpredictable microenvironment of cancerous cells in all of its existing forms i.e. leukaemic cells, solid tumours and sarcomas is well documented. This phenomenon expressed by cancerous sites in the body poses various obstacles towards drug efficacy. Thus, it has become necessary to address briefly the issues relating to tumour physiology, its vasculature and angiogenesis. The information could provide insight towards the development of tumour-targeted drug delivery. The salient features regarding these have been discussed.

show abstract

Section: Carrier Systems Formulation Remarksmentioning

confidence: 99%

Section: Enhanced Permeation and Retention (Epr) Effectmentioning

confidence: 99%

Tumour and dendrimers: a review on drug delivery aspects

Agarwal

Asthana

Gupta

et al. 2008

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…(e.g., drugs, radionuclides) have been achieved by From a chemical point of view all these polytheir conjugation to macromolecules. [3][4][5][6] Peptide meric polypeptides are rather similar, but their sideepitopes are attached to proteins or synthetic macromolecular carriers for construction the new generation of synthetic vaccines. [7][8][9] In order to contribute to the rational design of synthetic carrier, we have established structurefunction correlation by the introduction of new groups of branched polypeptides with the general formula poly[Lys-(X i -DL-Ala m )] (XAK) or poly-[Lys-(DL-Ala m -X i )] (AXK), where i õ 1, m Ç 3, and X represent an optically active residue.…”

Section: Introductionmentioning

confidence: 99%

Interaction of branched chain polymeric polypeptides with phospholipid model membranes

Nagy

Haro

Alsina³

et al. 1998

Biopolymers

View full text Add to dashboard Cite

The surface properties at the air/water interface and the interaction of branched chain polymeric polypeptides with a general formula poly[Lys‐(DL‐Alam‐X1)], where X = Π (AK), Ser (SAK), or Glu (EAK), with phospholipids were investigated. Polylysine derivatives with polycationic (SAK, AK) or amphoteric (EAK) were capable to spread and form stable monomolecular layers. The stability of monolayers at the air/water interface was dependent on the side‐chain terminal amino acid residue of polymers and can be described by SAK < AK < EAK order. The area per amino acid residue values calculated from compression isotherms were in the same range as compared to those of linear poly‐α‐amino acids and proteins. Moreover, these polymers interact with phospholipid monomolecular layers composed of dipalmitoyl phosphatidyl choline (DPPC) or DPPC/PG (PG: phosphatidyl glycerol; 95/5, mol/mol). Data obtained from compression isotherms of phospholipids spread on aqueous polymer solutions at different initial surface pressure indicated that insertion into lipid monolayers for SAK or AK is more pronounced than for EAK. The interaction between branched polypeptides and phospholipid membranes was further investigated using lipid bilayers with DPPC/PG and fluorescent probes located either at the polar surface [1‐(4‐trimethylammonium‐phenyl)‐6‐phenyl‐1,3,5‐hexatriene (TMA‐DPH) sodium anilino naphthalene sulfonate (ANS)] or within the hydrophobic core (DPH) of the liposome. Changes in fluorescence intensity and in polarization were observed when TMA‐DPH or ANS, but not DPH were used. Comparative data also indicate that all three polymers interact only with the outer surface of the bilayer, but even the most marked penetration of polycationic polypeptide (SAK) did not result in alteration of the ordered state of the alkyl chains in the bilayer. Taken together, data obtained from mono‐ or bilayer experiments suggest that the interaction between branched polymers and phospholipids are highly dependent on the charge properties (Ser vs Glu) and on the identity (Ser vs Ala) of side‐chain terminating amino acids. The binding of polymers to the model membranes could be mainly driven by electrostatic forces, but the significant role of hydrophilic properties in case of SAK cannot be excluded. © 1998 John Wiley & Sons, Inc. Biopoly 46: 169–179, 1998

show abstract

“…Delivery to a preselected intracellular organelle (e.g. lysosomes) is known as third-order targeting (1).…”

Section: Introductionmentioning

confidence: 99%

“…The following factors and requirements are of importance when considering the development of a drug-monoclonal antibody complex or conjugate for drug targeting (1)(2)(3).…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibodies in drug targeting

Panchagnula

Dey

1997

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

SUMMARYThe objective of drug targeting is to deliver drugs to a specific site of action through a carrier system. In cancer chemotherapy, cytotoxic drugs kill cancerous cells but also damage normal cells. Monoclonal antibodies generated against specific antigens, when conjugated to cytotoxic drugs, can selectively deliver drugs to cancer cells while minimizing damage to normal cells. Of all the carrier systems available, monoclonal antibodies are gaining importance because of their high specificity. The purpose of this review is to provide a comprehensive account of the use of monoclonal antibodies in drug targeting, highlighting their scope and limitations.

show abstract

Site‐specific drug delivery

Cited by 75 publications

References 216 publications

Tumour and dendrimers: a review on drug delivery aspects

Tumour and dendrimers: a review on drug delivery aspects

Interaction of branched chain polymeric polypeptides with phospholipid model membranes

Monoclonal antibodies in drug targeting

Contact Info

Product

Resources

About